A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

This study is testing a combination of targeted drugs — gefitinib, trametinib, disulfiram, and sunitinib — added to standard chemotherapy for people with osteosarcoma (a type of bone cancer). There are two groups: newly diagnosed patients with cancer that has spread, and patients whose cancer has returned after going into remission. **You may be eligible if...** - You have been newly diagnosed with metastatic (spread) osteosarcoma, especially with spread outside the lungs or with tumors that cannot be surgically removed, OR - Your osteosarcoma went into complete remission after treatment but has now come back within 24 months of starting first chemotherapy - You may have started standard chemotherapy but must join the study within 29 days of starting it - You are in good enough health to participate **You may NOT be eligible if...** - Your bone cancer has never spread or returned - You have already received too many cycles of prior chemotherapy - You have significant organ problems, active infections, or other serious health conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.